Search

Author/Creator Begbie, Stephen

1. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. Issue 5 (May 2020)

Authors:
Pfisterer, Jacobus; Shannon, Catherine M; Baumann, Klaus; Rau, Joern; Harter, Philipp; Joly, Florence; Sehouli, Jalid; Canzler, Ulrich; Schmalfeldt, Barbara; Dean, Andrew P; Hein, Alexander; Zeimet, Alain G; Hanker, Lars C; Petit, Thierry; Marmé, Frederik; El-Balat, Ahmed; Glasspool, Rosalind; de...
Journal:
Lancet oncology
Issue:
Volume 21:Issue 5(2020)
Page Start:
699
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. CTIM-24. NUTMEG: A RANDOMIZED PHASE II STUDY OF NIVOLUMAB AND TEMOZOLOMIDE VERSUS TEMOZOLOMIDE ALONE IN NEWLY DIAGNOSED ELDERLY PATIENTS WITH GLIOBLASTOMA. (14th November 2022)

Authors:
Sim, Hao-Wen; Lwin, Zarnie; Barnes, Elizabeth; McDonald, Kerrie; Yip, Sonia; Verhaak, Roel; Heimberger, Amy; Hall, Merryn; Wong, Matthew; Jennens, Ross; Ashley, David; Rosenthal, Mark; Hovey, Elizabeth; Ellingson, Benjamin; Tognela, Annette; Gan, Hui; Back, Michael; Koh, Eng-Siew; Long, Anne; Cuf...
Journal:
Neuro-oncology
Issue:
Volume 24(2022)Supplement 7
Page Start:
vii65
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. Issue 1 (January 2018)

Authors:
Colleoni, Marco; Luo, Weixiu; Karlsson, Per; Chirgwin, Jacquie; Aebi, Stefan; Jerusalem, Guy; Neven, Patrick; Hitre, Erika; Graas, Marie-Pascale; Simoncini, Edda; Kamby, Claus; Thompson, Alastair; Loibl, Sibylle; Gavilá, Joaquín; Kuroi, Katsumasa; Marth, Christian; Müller, Bettina; O'Reilly, Seam...
Journal:
Lancet oncology
Issue:
Volume 19:Issue 1(2018)
Page Start:
127
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial. Issue 4 (April 2023)

Authors:
Sweeney, Christopher J; Martin, Andrew J; Stockler, Martin R; Begbie, Stephen; Cheung, Leanna; Chi, Kim N; Chowdhury, Simon; Frydenberg, Mark; Horvath, Lisa G; Joshua, Anthony M; Lawrence, Nicola J; Marx, Gavin; McCaffrey, John; McDermott, Ray; McJannett, Margaret; North, Scott A; Parnis, Francis...
Journal:
Lancet oncology
Issue:
Volume 24:Issue 4(2023)
Page Start:
323
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗